Innovation Delaware: Bioscience
In 1991, CB Research and Development was founded in a 2,000-square-foot facility to synthesize specialized chemical compounds for drug-makers. There were three employees. That…
Tags: Jakafi
Incyte’s Jakafi gets FDA approval to treat GVHD
Incyte Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi® (ruxolitinib) for the treatment of steroid-refractory acute GVHD in…
Incyte wants to take on cancer with specialized therapies
Reid Huber, executive vice president and chief scientific officer at Incyte, has a simple formula for how the company can keep ahead in a…
Incyte reports second-quarter loss despite strong revenue
Incyte Corporation today reported a $12 million net loss for the fourth quarter, compared to net income of $34 million for the same period…
Jakafi helps drive Incyte revenues over $1 billion
Incyte Corporation, one of the region’s largest pharmaceutical companies, today reported fourth-quarter and year-end financial gains for 2016. The company attributes the success, in…
First patient treated with Incyte’s Jakafi
WILMINGTON — Incyte Corporation, based in Wilmington, has announced the first patient has been treated in the REACH-1 pivotal Phase 2 trial evaluating its…